Suppr超能文献

一项新诊断的非常年幼的 1 型糖尿病儿童使用胰岛素泵治疗和连续血糖监测的对比研究:有可能使 HbA1c 曲线变平。

A comparative study using insulin pump therapy and continuous glucose monitoring in newly diagnosed very young children with type 1 diabetes: it is possible to bend the curve of HbA1c.

机构信息

Department of Pediatrics, Pediatric Diabetology Unit, Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Via Olgettina, 60, 20132, Milan, Italy.

出版信息

Acta Diabetol. 2023 Dec;60(12):1719-1726. doi: 10.1007/s00592-023-02155-3. Epub 2023 Aug 1.

Abstract

AIMS

The target of metabolic control (HbA1c < 7% or 53 mmol/mol) recommended by the ADA and ISPAD is attained by 30% of children with Type 1 Diabetes (T1D). Advances in technologies for T1D aim to improve metabolic outcomes and reduce complications. This observational study assesses the long-term outcomes of advanced technologies for treatment of T1D compared to conventional approach started at onset in a group of very young children with T1D.

METHODS

54 patients with less 4 years old at onset of T1D were enrolled and followed for up to 9 years after diagnosis. 24 subjects started continuous subcutaneous insulin (CSII) treatment and 30 subjects received MDI therapy from onset. Auxological data, HbA1c and total daily insulin dose (TDD/kg) have been collected at admission and every 4 months. HbA1cAUC>6%, rates of acute complications, glycemic variability indices and glucometrics were also recorded.

RESULTS

Patients with CSII therapy had significantly lower mean HbA1c values compared to subjects receiving MDI treatment. CSII approach also recorded lower mean HbA1cAUC>6% and TDD/kg than MDI therapy. At the last download data, the time in range (TIR) was higher in patients with CSII and hyperglycemia events were lower. Better glycemic variability indices have been described during CSII therapy, including mean glycemia, standard deviation, coefficient of variation (CV), glycemia risk index (GRI) and high blood glucose index (HBGI). There was no statistically significant difference between frequency of severe hypoglycemia and ketoacidosis episodes between groups.

CONCLUSIONS

Early initiation of diabetes technologies is safe and able to determine a better long term glycemic control in young children with T1D. It also allows to flatten the trajectory of HbA1c, probably reducing microvascular, macrovascular and neurological complications of diabetes in this very peculiar age group.

摘要

目的

ADA 和 ISPAD 推荐的代谢控制目标(HbA1c<7%或53mmol/mol)仅在 30%的 1 型糖尿病(T1D)患儿中达到。T1D 治疗技术的进步旨在改善代谢结果并减少并发症。本观察性研究评估了与传统方法相比,在一组非常年幼的 T1D 患儿中,从发病开始即使用先进技术治疗 T1D 的长期结果。

方法

纳入了 54 名发病时年龄<4 岁的 T1D 患儿,并在诊断后最多随访 9 年。24 例患者开始接受持续皮下胰岛素(CSII)治疗,30 例患者从发病开始接受 MDI 治疗。在入院时和每 4 个月采集一次患者的生长数据、HbA1c 和每日胰岛素总剂量(TDD/kg)。还记录了 HbA1cAUC>6%、急性并发症发生率、血糖变异性指数和血糖仪数据。

结果

与接受 MDI 治疗的患者相比,接受 CSII 治疗的患者的平均 HbA1c 值显著降低。CSII 组的平均 HbA1cAUC>6%和 TDD/kg 也低于 MDI 治疗组。在最后一次下载数据时,CSII 组的血糖达标时间(TIR)更高,高血糖事件更少。CSII 治疗期间描述了更好的血糖变异性指数,包括平均血糖、标准差、变异系数(CV)、血糖风险指数(GRI)和高血糖指数(HBGI)。两组间严重低血糖和酮症酸中毒发作的频率无统计学差异。

结论

早期启用糖尿病技术是安全的,能够在年幼的 T1D 患儿中实现更好的长期血糖控制。它还可以使 HbA1c 的轨迹变平,可能会降低该非常特殊年龄组糖尿病的微血管、大血管和神经并发症的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验